Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
RESEARCH TOOLSreports
KalVista Pharmaceuticals (KALV) Stock Price & Analysis
335 Followers
KALV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.21 - $16.88
Previous Close$10.78
Volume241.42K
Average Volume (3M)814.59K
Market Cap
$472.93M
Enterprise Value$386.65M
Total Cash (Recent Filing)$75.59M
Total Debt (Recent Filing)$7.44M
Price to Earnings (P/E)-3.4
Beta0.82
Next Earnings
Jul 04, 2024EPS Estimate
-$0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.14
Shares Outstanding42,188,296
10 Day Avg. Volume342,683
30 Day Avg. Volume814,585
Standard Deviation0.26
R-Squared0.03
Alpha0.00602
Financial Highlights & Ratios
Price to Book (P/B)5.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.60
Forecast
1Y Price Target
$32.67Price Target Upside203.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
KalVista Pharmaceuticals News
PremiumCompany Announcements
KalVista Pharmaceuticals Welcomes New Board Member
PremiumCompany Announcements
KalVista Pharmaceuticals Announces Executive Leadership Transition
PremiumCompany Announcements
KalVista Pharmaceuticals Secures Funding to Advance Clinical ProgramsBulls Say, Bears Say
Bulls Say
Drug EfficacySebetralstat delivers positive on-demand therapy for HAE with early symptom relief, signaling a potential shift in treatment preferences for patients.
Market OutlookAnalyst expects sebetralstat to become the first-line on-demand HAE treatment, indicating a positive outlook for the drug's commercial success.
Trial ResultsThe Phase 3 KONFIDENT trial of sebetralstat met all primary and key secondary endpoints, bolstering analyst confidence in its market potential.
Bears Say
Clinical Trial ResultsThe stock could suffer significant losses if upcoming clinical trial results show a substantial decline from earlier Phase 2 outcomes.
Clinical Trial TimelineAnticipation of critical trial data has been pushed back, potentially deferring investor interest and negatively impacting stock performance.
Regulatory DelayInvestor confidence may wane due to continued postponements in the release of key study data, raising concerns about the underlying reasons.
---
Ownership Overview
73.44% Insiders
9.90% Mutual Funds
8.69% Other Institutional Investors
7.97% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KALV FAQ
What was KalVista Pharmaceuticals’s price range in the past 12 months?
KalVista Pharmaceuticals lowest stock price was $7.21 and its highest was $16.88 in the past 12 months.
What is KalVista Pharmaceuticals’s market cap?
Currently, no data Available
When is KalVista Pharmaceuticals’s upcoming earnings report date?
KalVista Pharmaceuticals’s upcoming earnings report date is Jul 04, 2024 which is in 67 days.
How were KalVista Pharmaceuticals’s earnings last quarter?
KalVista Pharmaceuticals released its earnings results on Mar 11, 2024. The company reported -$0.84 earnings per share for the quarter, missing the consensus estimate of -$0.747 by -$0.093.
Is KalVista Pharmaceuticals overvalued?
According to Wall Street analysts KalVista Pharmaceuticals’s price is currently Undervalued.
Does KalVista Pharmaceuticals pay dividends?
KalVista Pharmaceuticals does not currently pay dividends.
What is KalVista Pharmaceuticals’s EPS estimate?
KalVista Pharmaceuticals’s EPS estimate is -$0.7.
How many shares outstanding does KalVista Pharmaceuticals have?
KalVista Pharmaceuticals has 42,188,297 shares outstanding.
What happened to KalVista Pharmaceuticals’s price movement after its last earnings report?
KalVista Pharmaceuticals reported an EPS of -$0.84 in its last earnings report, missing expectations of -$0.747. Following the earnings report the stock price went down -8.774%.
Which hedge fund is a major shareholder of KalVista Pharmaceuticals?
Among the largest hedge funds holding KalVista Pharmaceuticals’s share is Driehaus Capital Management LLC. It holds KalVista Pharmaceuticals’s shares valued at 13M.
---
KalVista Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.67 (203.06% Upside)
$32.67 (203.06% Upside)
Blogger Sentiment
Bullish
KALV Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 340.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 11.4%
Last 30 Days ▼ 11.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.75%
12-Months-Change
Fundamentals
Return on Equity
-79.33%
Trailing 12-Months
Asset Growth
-43.99%
Trailing 12-Months
Company Description
KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.
---
KALV Stock 12 Months Forecast
Average Price Target
$32.67
▲(203.06% Upside)
Technical Analysis
Best Analysts Covering KALV
1 Year
1 Year Success Rate
9/19 ratings generated profit
1 Year Average Return
+4.97%
reiterated a buy rating 2 months ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 47.37% of your transactions generating a profit, with an average return of +4.97% per trade.
---